PedAM
Pediatric Disease Annotations & Medicines
| Disease | hodgkin disease |
| Phenotype | C0027947|neutropenia |
| Sentences | 8 |
| PubMedID- 24684228 | We conducted a cohort study to examine the association between a wide variety of chronic comorbidities and risk of febrile neutropenia (fn) in patients with non-hodgkin lymphoma (nhl) from 2000 to 2009 treated with chemotherapy at kaiser permanente southern california. |
| PubMedID- 26532567 | Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with non-hodgkin's lymphoma in greece. |
| PubMedID- 21687649 | This paper summarizes the evidence for managing abvd-related neutropenia during the treatment of hodgkin lymphoma. |
| PubMedID- 21472389 | Disseminated cryptococcosis in a non-hodgkin's lymphoma patient with late-onset neutropenia following rituximab-chop chemotherapy: a case report and literature review. |
| PubMedID- 22913768 | Economic costs of chemotherapy-induced febrile neutropenia among patients with non-hodgkin's lymphoma in european and australian clinical practice. |
| PubMedID- 23452152 | External validation of a risk model of febrile neutropenia occurrence in patients with non-hodgkin lymphoma. |
| PubMedID- 22536253 | In a phase i/ii dose-finding study, activity was observed in heavily pretreated nhl and hodgkin lymphoma (hl) patients, with neutropenia (47%) reported as the most frequent grade 3 or 4 toxicity [52]. |
| PubMedID- 22972488 | Primary prophylaxis with granulocyte colony-stimulating factor (gcsf) reduces the incidence of febrile neutropenia in patients with non-hodgkin lymphoma (nhl) receiving chop chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. |
Page: 1